Up next

Autoplay

HER-MES study: erenumab versus topiramate in episodic migraine

0 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Uwe Reuter, MD, PhD, MBA, Charité - University Medicine Berlin, Berlin, Germany, outlines the characteristics of the HER-MES study (NCT03828539), the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

Show more
0 Comments sort Sort By

Up next

Autoplay